Objective: The aim of our study was to identify potential predictive factors beyond pathologic response after neoadjuvant radiochemotherapy. Patients and Methods: Between January 2009 and December 2014, 40 patients with rectal carcinoma were included in the study. The treatment consisted of radiation ranging between 39 and 50.4 Gy associated with a concomitant chemotherapy with capecitabine. The correlation between histological response (complete response and downstaging) and potential predictive factors was investigated. Results: Complete response was 15% (06 patients), tumor regression of 32.5% (13 patients), and the absence of tumor response of 52.5% (21 patients). In univariate analysis, the circumferential extension of the tumor was significantly associated with tumor downstaging (p = 0.007) and complete tumor response (p = 0.001). However, the delay between the RCT and the surgery was a significant predictor for downstaging (p = 0.02). Conclusion: the parietal circumferential extension was a potential predictor of pathologic complete response (pCR) and downstaging after neoadjuvant chemoradiation. The time between the radiochemotherapy and the surgery was a significant predictor for downstaging. Delaying surgery beyond 8 weeks seems to result in the highest probability of pCR.
Introduction
Colorectal cancer (CRC) is the fourth most frequently diagnosed malignancy in both sexes and the second most common cause of cancer death in the world [1] . The advent of neoadjuvant radiotherapy in association with TME (Total Mesorectal Excision) surgery described by RJ Heald in 1982 [2] . has transformed the management of locally advanced forms (T3 T4 and / or N +) of middle and low rectal cancer, with a significant gain on local recurrence and an improvement in overall survival [3] . The association of chemotherapy with radiotherapy has further improved the carcinological and functional prognosis of this disease, favoring tumor regression (downstaging) or even tumor sterilization in some cases [4] . An interval of six to eight weeks between department at University Hospital Mohamed VI, Oujda, Morocco.
I n c l u s i o n c r i t e r i a f o r t h i s s t u d y w e r e included: biopsy-proven rectal cancer, tumor of the lower and middle rectum, classified as cT3-T4 with or without regional lymph node metastasis and no evidence of distant metastasis. Among reviewed 90 patients, 50 patients were excluded for the following reasons: patients had no curative surgery (the tumor is unresectable or the patients refuse surgery), and patients who were transferred to other hospitals could not be traced by medical records. Therefore, 40 patients who met the inclusion criteria were analyzed in this study.
Patients underwent Pre-therapeutic staging workups, including digital rectal examination, full blood counts, biochemical tumor markers (but concentration of pre-therapeutic ACE was not routinely required in all patients), colonoscopy with biopsy, chest radiography, abdominopelvic computed tomography (CT), pelvic magnetic resonance imaging (MRI). Endorectal ultrasonography (ERUS) was executed for one patient. Preoperative clinical stage was determined by CT scan, MRI, physical examination, or a combination of these.
Clinical and pathological characteristics of population are described in Table 1 . The study population was mostly females (57.5%) and had a median age of 56 years (range, 33 to 84 years). All the patients had a tumor within 10 cm from the anal verge: 57.5% of the tumors were in the lower rectum and 42.5% in the middle rectum. The tumors had involved more than 50% of the rectal circumference in 32.5% of the cases. During digital rectal examination, the tumor was fixed in 25%. Almost all patients had a cT3 classification of their primary tumor (95%).
The patients then received preoperative CRT in the form of preoperative whole-pelvis radiotherapy. The mean dose was 46 Gy (range, 39 to 50 Gy): 15% of the patients received hypofractionated radiotherapy with the dose of 39 Gy in 13 fractions, 35% received 46 Gy in 23 fractions and 50% received 50 Gy in 25 fractions with a sequential boost of 4 Gy. All patients underwent CT simulation for three-dimensional radiotherapy planning. Delineation of the clinical target volume (CTV) included the gross tumor volume, mesorectum, presacral space, whole of the sacral hollow and regional lymphatics. The boost CTV included the gross tumor volume with 1 cm margins. The relevant organs at risk volumes for this study were the bladder, femoral bones, and small bowel. The 6-MV or 18-MV photon beams were used for treatment plan. Dosimetric parameters were calculated using cumulative dose volume histogram data. Preoperative chemotherapy was initiated on the first day of pelvic radiotherapy and was delivered concurrently with radiotherapy. All patients received 825 mg / m 2 capecitabine orally twice daily, over the duration of radiotherapy with weekend breaks [7] . At the range of 32 to 137 days after the completion of preoperative RCT, all patients underwent a proctectomy associated with total mesorectal excision, with or without sphincter preservation. Anterior resection was performed in 19 patients (47.5%) and abdominoperineal resection in 21 patients (52.5%).
Histological examination of the operative specimen was performed to assess tumor type, histologic grade, number of retrieved and invaded LNs, maximum circumferential, distal extend, venous or perineural invasion, definitive staging (ypTNM after neoadjuvant treatment) evaluated according to the seventh edition of the UICC classification [8] Tumor regression grading (TRG) was done according to Dworak et al (Table 2 ) [9] .
As previously used and validated in one study, the tumor response, whether complete or partial (downstaging), was characterized by a reduction in pathological staging (yp Stage) relative to the pre-therapeutic stage (c Stage) [10] . We defined the complete histological response as the total absence of tumor cells on the operative pathologic specimen at both the primary site and in regional LNs (ypT0 N0), grade 4 of the Dworak classification (Table 2 ) [10, 11] . The downstaging was defined as the lowering of the T classification to a stage less than or equal to ypT2.
A univariate analysis was done by the log-rank test. This analysis consists in studying the complete response and downstaging, after neoadjuvant treatment in middle and lower rectal cancer, as a function of various potential predictors factors: age, sex, circumferential extent of tumor, tumor fixation, Distance from anal verge, Tumor differentiation, hemoglobin level, clinical T classification, clinical lymph node (N) classification, radiation dose, and time between RCT and surgery. Multivariate analysis could not be done due to the lack of power due to low numbers. The analysis were performed with IBM SPSS statistics trial ver. 20.0 (IBM, Armonk, NY, USA). A p-values of <0.05 were considered to indicate a significant difference.
Results
Pathologic examination of resected specimens revealed complete histopathological response (pCR) in 06 patients (15%). Downstaging to ypT2 or less was observed in 19 patients (47,5%). Twenty-one patients (52,5%) showed no downstaging of either T or N stage and were classified as non-responders (Table 3 ). The tumor was classified as ypT0 in 6 patients (15%), ypT1 in 4 (10%), ypT2 in 9 (22.5%), ypT3 in 19 (47.5%) and ypT4 in two (5%).
The univariate analysis indicated that the circumferential extent of the tumor was significantly associated with tumor downstaging (p = 0.007) and with a complete tumor response (p = 0.001). However, a delay between RCT and surgery ≥ 8 weeks was a significant predictive factor for downstaging (p = 0.02). Other variables (sex, age, Tumor localization, tumor fixation, anemia, Distance from the anal verge, , Tumor differentiation, clinical T classification, clinical lymph node (N) classification, radiation dose) were not significantly correlated with downstaging (Table 4 and 
The interval from the end of radiation to surgery has been of special interest and has been directly addressed by multiple studies as well as a meta-analysis [13] . Although the exact ideal interval to optimize pCR has not been identified, the overall conclusion from these studies is that pCR rates improve with delaying surgery by more than 6-8 weeks after the end of RCT. In this context, curative surgical treatments performed at six weeks from the end of the RCT may have interrupted ongoing necrosis, which means that some patients may achieve complete tumor regression if waiting times were longer [14] . Kalady et al. in 2009 [15] had shown that interval ≥ 8 weeks
Discussion
The factors that predict the response to neoadjuvant radiation chemotherapy in rectal cancer have not yet been well determined. Some recent studies also have investigated potential predictors of pCR and downstaging.
Tumor circumference can serve as an important predictor of pathological tumor response. This was demonstrated in the study by Das et al [12] . In this study, the results of univariate and multivariate analysis indicate that circumferential extent of tumor (less than 60%) predicts significantly the complete response rate and downstaging. These results agree with those of our study, the circumferential extenst of tumor was significantly 
Grade 3
Very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance.
Grade 4
No tumor cells, only fibrotic mass (total regression or response) Table 2 . Dworak Regression Grade [9] PRE (cTN) POST (ypTN)  TOTAL   T0N0  T0N+  T1N0  T1N+  T2N0  T2N+  T3N0  T3N+  T4N0  T4N+   T3N0  4  0  0  2  7  0  6  6  0  0  25   T3N+  2  0  2  0  0  2  3  4  0  0 [16] . showed that Delaying surgery until 10-11 weeks after the end of RCT was significantly correlated with the complete histological response (p = 0.013). A recently published study using NCDB data provided the largest dataset focusing on the question of the interval from the end of nCRT to surgery, and concurred with the published literature that an interval of more than 8 weeks is associated with increased rates of complete response [17] . In our study, the time between RCT and surgery was not correlated with a complete response (p = 0.3). However, a delay of ≥ 8 weeks was a predictor of downstaging (p = 0.02). These findings are consistent with other recent studies, where they observed more downstaging and better surgical results with a delay of more than 8 weeks [18] . The largest published dataset to date [19] , dealing with predictive factors of pCR after preoperative RCT in 23747 patients with rectal cancer, is consistent with those findings but, furthermore, offer additional variables that can help identify those patients most likely to respond (lower tumor grade, lower clinical T and N stage and higher radiation dose, while lack of health insurance was linked with a lower likelihood of pCR). Other studies have reported some variables that were not included in this study, such as low pretreatment CEA level [20] [21] [22] [23] [24] [25] , low CEA level after RCT [26, 27] , small pre- [28, 29] and post-treatment tumor size [30] , pre-treatment tumor mobility on digital rectal examination [30] , low clinical lymph node (N) classification [28] , low tumor grade [31, 32] , shorter distance from the anal verge [12, 31] , low neutrophil to lymphocyte ratio [29] , type of concurrent chemotherapy used [33] and higher radiation dose [34] . These factors are subjective parameters that are susceptible to inter-observer variations, and it is difficult to assess these factors in a retrospective study.
In conclusion, the identification of predictive factors for tumor response could have potential therapeutic applications. The increase in the rates of complete or partial histological responses has led to the emergence of the concept of conservative approaches such as a wait-and-see strategy [35] . Further studies are required to determine strategies for optimizing the oncological outcome on an individual basis.
